Table I.
Sample | Diagnosis | Score | CR vs. IR | Debulking | Age (years) | Stage | CA125 |
---|---|---|---|---|---|---|---|
1 | Focal adenocarcinoma | 6 | CR | O | 57 | IIIC | 541 |
2 | Papillary serous adenocarcinoma | 1 | CR | O | 84 | IIIC | 7350 |
3 | Adenocarcinoma | 2 | CR | O | 53 | IIIC | |
4 | Papillary serous adenocarcinoma | 4 | CR | O | 61 | IIIC | |
5 | Papillary serous adenocarcinoma | 6 | CR | O | 57 | IIIC | |
6 | Papillary serous adenocarcinoma | 1 | CR | O | 55 | IV | |
7 | Papillary serous adenocarcinoma | 2 | CR | O | 49 | IIIC | 305 |
8 | Papillary serous adenocarcinoma | 1 | CR | O | 65 | IIIC | |
9 | Papillary serous adenocarcinoma | 4 | CR | O | 60 | IIIC | 925 |
10 | Papillary serous adenocarcinoma | 2 | CR | O | 51 | IIIB | |
11 | Papillary serous adenocarcinoma | 4 | CR | O | 56 | IIIC | 316 |
12 | Papillary serous adenocarcinoma | 2 | CR | O | 66 | IIIC | 224 |
13 | Papillary serous adenocarcinoma | 2 | CR | S | 56 | IIIC | |
14 | Papillary serous adenocarcinoma | 4 | CR | O | 73 | IIIC | |
15 | Papillary serous adenocarcinoma | 1 | CR | O | 62 | IIIC | 1717 |
16 | Papillary serous adenocarcinoma | 2 | CR | O | 78 | IIIC | |
17 | Papillary serous adenocarcinoma | 6 | CR | O | 43 | IIIC | 64 |
18 | Papillary serous adenocarcinoma | 1 | CR | O | 45 | IIIC | |
19 | Papillary serous adenocarcinoma | 1 | CR | S | 74 | IIIC | 1800 |
20 | Papillary serous adenocarcinoma | 2 | CR | O | 76 | IIIC | |
21 | Papillary serous adenocarcinoma | 2 | IR | S | 79 | IV | |
22 | Papillary serous adenocarcinoma | 2 | IR | S | 71 | IV | 1636 |
23 | Papillary serous adenocarcinoma | 2 | CR | O | 56 | IIIC | |
24 | Papillary serous adenocarcinoma | 1 | CR | O | 81 | IIIC | |
25 | Papillary serous adenocarcinoma | 2 | CR | O | 56 | IIIC | 260 |
26 | papillary serous adenocarcinoma | 3 | CR | O | 35 | IV | 47 |
27 | Papillary serous adenocarcinoma | 2 | CR | O | 53 | IIIA | |
28 | Papillary serous adenocarcinoma | 1 | CR | S | 77 | IV | >600 |
29 | Papillary serous adenocarcinoma | 2 | CR | O | 65 | IIIC | 1118 |
30 | Papillary serous adenocarcinoma | 1 | CR | S | 47 | IIIC | 712 |
31 | Papillary serous adenocarcinoma | 2 | CR | S | 76 | IIIC | 1848 |
32 | Papillary serous adenocarcinoma | 2 | CR | O | 70 | IIIC | |
33 | Papillary serous adenocarcinoma | 3 | CR | S | 57 | IIIC | 266 |
34 | Adenocarcinoma metastatic | 2 | CR | O | 57 | IIIC | 175 |
35 | Papillary serous adenocarcinoma | 1 | CR | O | 65 | IV | 404 |
36 | Papillary serous adenocarcinoma | 2 | CR | O | 76 | IV | |
37 | Papillary serous adenocarcinoma | 1 | CR | O | 66 | IIIC | |
38 | Papillary serous adenocarcinoma | 1 | CR | O | 68 | IIIC | |
39 | Papillary serous adenocarcinoma | 3 | IR | O | 73 | IIIC | |
40 | Papillary serous adenocarcinoma | 2 | CR | O | 63 | IV | |
41 | Papillary serous adenocarcinoma | 2 | IR | S | 63 | IIIC | |
42 | Papillary serous adenocarcinoma | 2 | IR | O | 47 | IIIC | |
43 | Papillary serous adenocarcinoma | 2 | CR | O | 42 | IIIC | 110 |
44 | Papillary serous adenocarcinoma | 1 | CR | O | 74 | IIIC | 4557 |
45 | Papillary serous adenocarcinoma | 2 | CR | S | 64 | IIIC | |
46 | Papillary serous adenocarcinoma | 2 | IR | S | 64 | IIIC | 456 |
47 | Papillary serous adenocarcinoma | 1 | IR | O | 71 | IIIC | |
48 | Papillary serous adenocarcinoma | 6 | IR | O | 69 | IIIC | |
49 | Papillary serous adenocarcinoma | 3 | CR | O | 49 | IIIC | |
50 | Papillary serous adenocarcinoma | 2 | CR | O | 62 | IV | |
51 | Papillary serous adenocarcinoma | 2 | IR | ||||
52 | Focal adenocarcinoma | 3 | CR | S | 88 | IIIC | |
53 | Serous adenocarcinoma | 1 | IR | O | 74 | IIIC | 101 |
54 | Papillary serous adenocarcinoma | 2 | IR | O | 71 | IIIC | |
55 | Papillary serous adenocarcinoma | 4 | IR | O | 69 | IIIC | 1606 |
56 | Papillary serous adenocarcinoma | 1 | IR | O | 52 | IIIC | |
57 | Papillary serous adenocarcinoma | 2 | CR | O | 67 | IIIC | |
58 | Papillary serous adenocarcinoma | 1 | CR | O | 66 | IIIC | 824 |
59 | Papillary Serous adenocarcinoma | 2 | IR | O | 52 | IIIC | |
60 | Papillary serous adenocarcinoma | 1 | CR | S | 73 | IIIC | 2354 |
61 | Papillary serous adenocarcinoma | 0 | CR | O | 75 | IIIC | |
62 | Papillary serous adenocarcinoma | 2 | IR | O | 65 | IIIC | |
63 | Focal cellular atypia | n/a | CR | O | 74 | IIIC | |
64 | Papillary serous adenocarcinoma | 2 | IR | O | 79 | IIIC | 417 |
65 | Papillary serous adenocarcinoma | 1 | CR | O | 73 | IIIC | 180 |
66 | Papillary serous adenocarcinoma | 2 | IR | O | 53 | IV | 96 |
67 | Papillary serous adenocarcinoma | 1 | CR | O | 60 | IIIC | |
68 | Papillary serous adenocarcinoma | 2 | CR | ||||
69 | Papillary serous adenocarcinoma | 2 | IR | S | 53 | IIIC | |
70 | Papillary serous adenocarcinoma | 1 | IR | O | 41 | IIIC | 2800 |
71 | Papillary serous adenocarcinoma | 1 | CR | O | 80 | IIIC | |
72 | Papillary serous adenocarcinoma | 2 | CR | O | 42 | IIIA | |
73 | Papillary serous adenocarcinoma | 2 | IR | S | 66 | IIIC | 90 |
74 | Papillary serous adenocarcinoma | 1 | CR | S | 60 | IIIC | 750 |
75 | Papillary serous adenocarcinoma | 4 | CR | O | 77 | IIIC | 9814 |
76 | Papillary serous adenocarcinoma | 0 | CR | O | 72 | III | |
77 | Papillary serous adenocarcinoma | 1 | IR | O | 66 | IIIC | |
78 | Papillary serous adenocarcinoma | 0 | CR | O | 54 | III | |
79 | Papillary serous adenocarcinoma | 3 | CR | O | 38 | IIIC |
The c-Met expression score was determined by intensity × cellularity, where intensity was graded as 1, weak; 2, moderate; or 3, strong, and cellularity was graded as 1 when ≤33%, 2 when 34–65%, or 3 when ≥66%. CR, complete response; IR, incomplete response to primary therapy.